Literature DB >> 21606223

Comparative activities of tigecycline and other tetracyclines against nonfermenting Gram-negative bacilli, excluding Acinetobacter spp.

Marisa N Almuzara, Maria Isabel Encalada Barzallo, Angela M R Famiglietti, Carlos A Vay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21606223      PMCID： PMC3147617          DOI： 10.1128/AAC.00438-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  14 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia.

Authors:  R Insa; E Cercenado; M J Goyanes; A Morente; E Bouza
Journal:  J Antimicrob Chemother       Date:  2007-01-09       Impact factor: 5.790

4.  Tigecycline and colistin susceptibility of Chryseobacterium meningosepticum isolated from blood in Taiwan.

Authors:  Yi-Tsung Lin; Yu-Jiun Chan; Cheng-Hsun Chiu; Mei-Lin Lin; Kwok-Woon Yu; Fu-Der Wang; Cheng-Yi Liu
Journal:  Int J Antimicrob Agents       Date:  2009-03-03       Impact factor: 5.283

5.  16S ribosomal DNA amplification for phylogenetic study.

Authors:  W G Weisburg; S M Barns; D A Pelletier; D J Lane
Journal:  J Bacteriol       Date:  1991-01       Impact factor: 3.490

6.  Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia.

Authors:  Carmen Betriu; Iciar Rodríguez-Avial; Blas Ali Sánchez; María Gómez; Juan J Picazo
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

Review 7.  Tigecycline: a new glycylcycline for treatment of serious infections.

Authors:  Gary A Noskin
Journal:  Clin Infect Dis       Date:  2005-09-01       Impact factor: 9.079

Review 8.  Tigecycline: a critical analysis.

Authors:  Gary E Stein; William A Craig
Journal:  Clin Infect Dis       Date:  2006-06-26       Impact factor: 9.079

9.  Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).

Authors:  Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2011-02       Impact factor: 2.803

10.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191
View more
  1 in total

Review 1.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.